Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.